Table 6.

Frequency distributions of PFA IC50s for recent clinical isolates using the ACTG consensus protocol

PFA IC50 (μM)No. of assays with IC50 at each PFA concn
CMV 1aCMV 2CMV 3CMV 4CMV 5CMV 6
   <252
 >25–50   121
 >50–100  1113
>100–200  221463
>200–400  442415
>400–800  2121
>800–1,600212
>1,60041
Total no. of assays10b 10b 11c 121211c
Median IC50 227.65200.14855.85184.84117.19325.18
No. (%) resistant2 (20)1 (10)8 (73)1 (8)1 (8)3 (27)
  • a CMV 1 to 6 were not plaque purified.

  • b Data not submitted by two laboratories.

  • c IC50 could not be determined for one data set due to inconsistent results.